Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus versus mycophenolic acid in simultaneous pancreas-kidney transplantation
2013-004934-14Phase 4Completed
- Sponsor
- Institute for Clinical and Experimental Medicine
- Start
- Jan 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in diabetes mellitus type 1 (T1D), end-stage kidney disease (ESKD), Post-Transplant Immunosuppression and 1 more comparing Everolimus (Certican)-based immunosuppression with Mycophenolic acid (Myfortic)-based immunosuppression (2 arms). Primary endpoint: Need for unscheduled laser therapy. Started Jan 2014; status: completed.
02
Drugs
everolimusmycophenolate sodium
03
Conditions
diabetes mellitus type 1 (T1D)end-stage kidney disease (ESKD)Post-Transplant Immunosuppressiondiabetic retinopathy (DR)
Beyond the preview
Go deeper on 2013-004934-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004934-14.